Methotrexate

What is it?

Methotrexate represents a cornerstone systemic therapy classified as an antifolate antimetabolite (medication that interferes with folate metabolism), originally developed for cancer treatment but now extensively utilized for inflammatory dermatological conditions. This immunosuppressive agent demonstrates potent anti-inflammatory and antiproliferative properties through inhibition of cellular DNA synthesis and inflammatory mediator production. Methotrexate has established itself as a first-line systemic treatment for moderate-to-severe psoriasis and serves as an effective steroid-sparing agent for various inflammatory skin conditions.

What are the indications?

Methotrexate demonstrates established efficacy across multiple dermatological and rheumatological conditions:

• Main indications:
  • Moderate-to-severe psoriasis (plaque, pustular, and erythrodermic variants)
  • Psoriatic arthritis with cutaneous manifestations
  • Severe atopic dermatitis refractory to conventional therapy
• Secondary indications:
  • Cutaneous T-cell lymphoma (mycosis fungoides)
  • Severe dermatomyositis and systemic lupus erythematosus
  • Bullous pemphigoid and pemphigus vulgaris as adjunctive therapy
• Off-label uses:
  • Hidradenitis suppurativa, sarcoidosis, and severe alopecia areata

How does it work?

Methotrexate exerts therapeutic effects through multiple complementary mechanisms targeting inflammatory pathways:

• Primary mechanism: Inhibition of dihydrofolate reductase enzyme, preventing conversion of dihydrofolate to tetrahydrofolate, thereby disrupting DNA synthesis and cellular proliferation
• Therapeutic effect: Reduction in keratinocyte hyperproliferation, suppression of T-cell activation, and decreased production of inflammatory cytokines (TNF-α, IL-1β, IL-6)
• Onset of action: Clinical improvement typically observed within 6-8 weeks of initiation, with maximum therapeutic benefit achieved at 12-16 weeks

How is it used?

Methotrexate administration follows established protocols for optimal efficacy and safety:

• Method of administration: Oral tablets taken once weekly (subcutaneous injection for malabsorption or gastrointestinal intolerance)
• Typical dosing schedule: Starting dose 5-7.5mg weekly, gradually increased by 2.5-5mg increments every 2-4 weeks to effective maintenance dose of 10-25mg weekly
• Duration of treatment: Long-term therapy often required, with regular assessment for continued benefit and safety
• What to expect: Initial improvement within 6-8 weeks, with optimal response achieved by 12-16 weeks of therapy

What are the adverse reactions?

Methotrexate adverse effects demonstrate dose-dependent patterns and require systematic monitoring:

• Common reactions (experienced by many patients):
  • Gastrointestinal disturbances (nausea, vomiting, diarrhea, oral ulceration)
  • Fatigue and malaise (particularly 24-48 hours post-dose)
  • Elevated liver enzymes (transaminase elevation in 15-30% of patients)
• Less common reactions (experienced by some patients):
  • Hair thinning or alopecia (usually reversible)
  • Photosensitivity reactions with increased UV sensitivity
  • Mild cognitive effects (difficulty concentrating, mood changes)
• Serious reactions (rare but important to recognize):
  • Hepatotoxicity with potential progression to fibrosis or cirrhosis
  • Bone marrow suppression (leucopenia, thrombocytopenia, anemia)
  • Pulmonary toxicity (pneumonitis, pulmonary fibrosis)

Who should not use it?

Methotrexate carries absolute and relative contraindications requiring careful screening:

• Absolute contraindications:
  • Pregnancy and breastfeeding (teratogenic effects)
  • Active or chronic infection (immunosuppression risk)
  • Significant hepatic impairment or active liver disease
• Relative contraindications:
  • Renal insufficiency (creatinine clearance <60 mL/min)
  • Active peptic ulcer disease or inflammatory bowel disease
  • Significant pulmonary disease or pleural effusion
• Special precautions:
  • Elderly patients require dose reduction and enhanced monitoring
  • Concurrent medication interactions (particularly NSAIDs, trimethoprim-sulfamethoxazole)

Tips for getting the most out of treatment

Maximizing therapeutic benefits:

• Ensure consistent weekly dosing schedule with same day administration each week
• Optimize concurrent folic acid supplementation (1mg daily or 5mg weekly on non-methotrexate days)
• Maintain adequate hydration and avoid excessive alcohol consumption

Minimizing adverse reactions:

• Administer with food to reduce gastrointestinal irritation and improve tolerance
• Divide weekly dose into 2-3 smaller doses taken over 24-hour period if experiencing significant nausea
• Schedule laboratory monitoring consistently (monthly for first 3 months, then every 3 months during stable therapy)

Lifestyle considerations:

• Limit alcohol consumption to ≤2 units per week to minimize hepatotoxicity risk
• Avoid live vaccines during treatment period due to immunosuppression
• Implement rigorous infection precautions and seek prompt medical attention for fever or signs of infection